Cost analysis of photobiomodulation in tibia fracture in the Brazilian public health system

PLoS One. 2023 Dec 8;18(12):e0294290. doi: 10.1371/journal.pone.0294290. eCollection 2023.

Abstract

Managing tibial fractures requires substantial health resources, which costs the health system. This study aimed to describe the costs of photobiomodulation (PBM) with LEDs in the healing process of soft tissue lesions associated with tibial fracture compared to a placebo. Economic analysis was performed based on a randomized controlled clinical trial, with a simulation of the cost-effectiveness and incremental cost model. Adults (n = 27) hospitalized with tibia fracture awaiting definitive surgery were randomized into two distinct groups: the PBM Group (n = 13) and the Control Group with simulated phototherapy (n = 14). To simulate the cost-effectiveness and incremental cost model, the outcome was the evolution of wound resolution by the BATES-JENSEN scale and time of wound resolution in days. The total cost of treatment for the Control group was R$21,164.56, and a difference of R$7,527.10 more was observed when compared to the treatment of the PBM group. The proposed intervention did not present incremental cost since the difference in the costs to reduce measures between the groups was smaller for the PBM group. When analyzing the ICER (Incremental cost-effectiveness ratio), it would be possible to save R$3,500.98 with PBM and decrease by 2.15 points in the daily average on the BATES-JENSEN scale. It is concluded, therefore, that PBM can be a supportive therapy of clinical and economic interest in a hospital setting.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Brazil
  • Cost-Benefit Analysis
  • Costs and Cost Analysis
  • Humans
  • Low-Level Light Therapy*
  • Public Health
  • Tibia
  • Tibial Fractures* / therapy

Grants and funding

KPSF, SKB and RAMF were supported by CNPq - National Council for Technological and Scientific Development (CNPq, grant n. 304330/2020-5, n. 306577/2020-8 and n.310491/2021-5). The sponsors had no role in the design, execution, interpretation, or writing of the study.